MRNA vaccine takes on Hard-to-Treat cancers
NCT ID NCT07363369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a therapeutic mRNA vaccine that targets a protein called FAP found on cancer-supporting cells. The goal is to help the immune system attack the tumor's defenses. Ten adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) who have run out of standard options will receive the vaccine along with immune checkpoint inhibitors. The main focus is safety, but researchers will also look for signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FAP mRNA vaccine combined with immune checkpoint inhibitors
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 10 participants, so it is primarily testing safety. The vaccine may not shrink tumors or improve survival, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.